 "Dr Reddy's launches Nitroglycerin tablets in the US")
Dr Reddy's Laboratories Limited on Monday announced that it has launched Nitroglycerin sublingual tablets USP, 0.3 mg, 0.4 mg and 0.6 mg, a therapeutic equivalent generic version of Nitrostat in the US market on August 26, following the approval from the US Food and Drug Administration (USFDA).
The Nitrostat had US sales of approximately $108 million for the most recent twelve months ending in March 2016, the company said citing the IMS data.
Nitroglycerin is a vasodilator, a medicine that opens blood vessels to improve blood flow and is used to treat patients complaining of chest pain among other symptoms.
The company scrip was up Rs 9.50 at Rs 3,049.75 in the afternoon trade on Bombay Stock Exchange on Tuesday.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app